Goldman Sachs Group Inc. Boosts Stock Position in BioNTech SE (NASDAQ:BNTX)

Goldman Sachs Group Inc. lifted its position in shares of BioNTech SE (NASDAQ:BNTX) by 17.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 182,878 shares of the company’s stock after buying an additional 26,777 shares during the period. Goldman Sachs Group Inc. owned about 0.08% of BioNTech worth $19,301,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CWM LLC raised its stake in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after acquiring an additional 217 shares in the last quarter. Frazier Financial Advisors LLC bought a new stake in BioNTech in the fourth quarter worth $30,000. Covestor Ltd purchased a new stake in BioNTech during the third quarter valued at about $32,000. First Horizon Advisors Inc. purchased a new stake in BioNTech during the fourth quarter valued at about $38,000. Finally, UMB Bank n.a. bought a new position in shares of BioNTech during the fourth quarter valued at about $50,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 2.2 %

Shares of BNTX opened at $82.52 on Thursday. BioNTech SE has a 1-year low of $82.04 and a 1-year high of $125.83. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $92.46 and its 200-day moving average price is $94.94. The firm has a market capitalization of $19.62 billion, a price-to-earnings ratio of 165.04 and a beta of 0.27.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The firm had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Sell-side analysts anticipate that BioNTech SE will post -2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BNTX. Evercore ISI started coverage on BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price for the company. UBS Group cut their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $113.00 target price on shares of BioNTech in a research note on Wednesday. BMO Capital Markets dropped their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Finally, TD Cowen boosted their price objective on shares of BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $111.70.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.